Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded by StockNews.com to Buy

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

Separately, Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday.

Supernus Pharmaceuticals Trading Up 0.9 %

Shares of SUPN opened at $32.06 on Thursday. The firm has a market capitalization of $1.77 billion, a P/E ratio of 29.96 and a beta of 0.90. Supernus Pharmaceuticals has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a fifty day moving average price of $37.12 and a 200-day moving average price of $35.34.

Insider Activity at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last three months. 9.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Raiffeisen Bank International AG bought a new position in Supernus Pharmaceuticals in the fourth quarter worth about $25,000. GF Fund Management CO. LTD. bought a new position in Supernus Pharmaceuticals in the fourth quarter worth about $42,000. Smartleaf Asset Management LLC raised its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter worth about $52,000. Finally, Headlands Technologies LLC raised its holdings in Supernus Pharmaceuticals by 203.0% in the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.